Dong-Wan Kim
Dong-Wan Kim is a thoracic oncologist central to the ALK and ROS1 inhibitor trials, from crizotinib to brigatinib and beyond.
Dong-Wan Kim has been an investigator on the PROFILE, ALTA, and later ALK/ROS1 trials and on EGFR studies, helping establish targeted therapy for fusion-driven lung cancer.
| Title | Journal | Year |
|---|---|---|
| Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer (ALTA-1L) | NEJM | 2018 |
Pages like this
not linked directly; found by shared links- PersonBenjamin Solomon
Shares CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer, Lorlatinib, ALK, Non-small-cell lung cancer.
- ProductZidesamtinib
Shares Repotrectinib, ROS1, Non-small-cell lung cancer.
- PersonAlexander Drilon
Shares Repotrectinib, ROS1, Non-small-cell lung cancer.
- InstitutionUniversity of Colorado Cancer Center
Shares ROS1, Lorlatinib, ALK, Non-small-cell lung cancer.
- PersonJustin F. Gainor
Shares Lorlatinib, ALK, Non-small-cell lung cancer.
- TrialCROWN
Shares Lorlatinib, ALK, Non-small-cell lung cancer.
- PairingSequence: targeted therapy before immunotherapy in driver-positive NSCLC
Shares ROS1, Lorlatinib, ALK, Non-small-cell lung cancer.
- CollectionLUNGevity Foundation (and GO2 for Lung Cancer)
Shares ROS1, ALK, Non-small-cell lung cancer.